Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial Eli O. Meltzer, MDa,

Slides:

Advertisements

Similar presentations

Downloaded from – Use of Montelukast for the Treatment of Seasonal (Spring) Allergic Rhinitis.

Advertisements

W.Travis Cain, MDa, Greg Cable, PhDb, John J. Oppenheimer, MDc

Tuomo Puhakka, MDa, Mika J

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis Fuad M. Baroody, MD, David Brown, MD,

Double-blind placebo-controlled study of the efficacy of oral terfenadine in the treatment of chronic fatigue syndrome Paul Steinberg, MDa, Bruce E.

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy Monica B. Arvidsson, MD, Olle.

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses Stephen R. Durham,

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study Eli O. Meltzer, MD, Paul.

Ulrich Wahn, MDa. ‡, Eli O. Meltzer, MDb. ‡, Albert F. Finn, MDc

Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction Robert A. Nathan, MDa, Jonathan A.

Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials Javier Dibildox,

A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis William R. Lumry, MD Journal of.

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses Stephen R. Durham,

A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children Mark Boguniewicz, MDa, Virginia C. Fiedler,

Richard L. ZuWallack, MD a,b, James P

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis

The effect of omalizumab on nasal allergic inflammation

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis Paul H. Ratner,

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials Javier Dibildox,

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis James.

As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,

Edwin A. Bronsky, MD, Howard Druce, MD, Steven R. Findlay, MD, Frank C

Harold B. Kaiser, MDa, Steven R. Findlay, MD†, John W

Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis

Elinor Simons, MDa, William M

Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trial William Busse, MDa,

Low-dose levalbuterol in children with asthma: Safety and efficacy in comparison with placebo and racemic albuterol Henry Milgrom, MDa, David P. Skoner,

Serum levels of eosinophil cationic protein in allergic diseases and natural allergen exposure Margherita Tomassini, MDa, Laura Magrini, MDa, Guido De.

Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid–dependent, persistent asthma Gail.

Anaphylactic reaction to local administration of rifamycin SV

Allergic rhinoconjunctivitis caused by Harmonia axyridis (Asian lady beetle, Japanese lady beetle, or lady bug) John A. Yarbrough, MDa, Jack L. Armstrong,

Randomized, double-blind, crossover challenge study in 53 subjects reporting adverse reactions to melon (Cucumis melo) Julia Rodriguez, MDa, Jesus F.

Effect of intranasal azelastine and beclomethasone dipropionate on nasal symptoms, nasal cytology, and bronchial responsiveness to methacholine in allergic.

A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model John M.

A review of the current guidelines for allergic rhinitis and asthma

Physician-targeted program on inhaled therapy for childhood asthma

James P. Kemp, MDa, David A. Cook, MDb, Gary A

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, double-blind, placebo-controlled.

Efficacy of nebulized budesonide in treatment of severe infantile asthma: A double-blind study Jacques de Blic, MDa, Christophe Delacourt, MDa, Muriel.

Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray Eli O. Meltzer,

Nasal eosinophilia and IL-5 mRNA expression in seasonal allergic rhinitis induced by natural allergen exposure: Effect of topical corticosteroids Keisuke.

Exercise-induced bronchoconstriction in children: Montelukast attenuates the immediate-phase and late-phase responses Raul E. Melo, MD, Dirceu Solé,

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

Thomas B. Casale, MDa, I. Leonard Bernstein, MDb, William W

Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic.

A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray

Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma Eugene R. Bleecker, MDa, Michael J. Welch, MDb,

Omalizumab improves asthma-related quality of life in patients with severe allergic asthma Albert Finn, MDa, Gary Gross, MDb, Julius van Bavel, MDc,

A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein.

Loratadine reduces allergen-induced mucosal output of α2-macroglobulin and tryptase in allergic rhinitis Lennart Greiff, MD, PhDa, Carl G.A. Persson,

Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled.

The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis Matthias Volkmar Kopp, MDa, Jens Brauburger,

Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen–induced seasonal allergic rhinitis Ellinor Ädelroth, MD, PhDa, Sabina Rak, MD, PhDb,

Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma James P.

Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib Pär Gyllfors,

An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment Eli O. Meltzer, MD, Robert B. Berkowitz,

Short course of systemic corticosteroids in sinonasal polyposis: A double-blind, randomized, placebo-controlled trial with evaluation of outcome measures

Tuomo Puhakka, MDa, Mika J

Larry C. Borish, MDa, Harold S

Thomas J. Kirby, MDa (by invitation), Michael J

A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis Warner Carr, MD, Jonathan Bernstein, MD, Phil Lieberman,

Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal.

The correlation between allergic rhinitis and sleep disturbance

The effects of an H3 receptor antagonist (PF ) with fexofenadine on reducing allergic rhinitis symptoms Jeffrey R. Stokes, MD, Francisco A. Romero,

Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal.

An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment Eli O. Meltzer, MD, Robert B. Berkowitz,

Desloratadine: A new, nonsedating, oral antihistamine

Presentation transcript:

Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial Eli O. Meltzer, MDa, Kerstin Malmstrom, PhDb, Susan Lu, PharmDb, Bruce M. Prenner, MDc, Lynn X. Wei, PhDb, Steven F. Weinstein, MDd, James D. Wolfe, MDe, Theodore F. Reiss, MDb Journal of Allergy and Clinical Immunology Volume 105, Issue 5, Pages 917-922 (May 2000) DOI: 10.1067/mai.2000.106040 Copyright © 2000 Mosby, Inc. Terms and Conditions

Fig. 1 Effect on individual daytime nasal symptoms: nasal congestion, rhinorrhea, nasal itching, and sneezing for each treatment group. The data were collected on daily diary cards using a 0 (= best) to 3 (= worst) scale. Baseline values (score ± SD) were nasal congestion (stuffy nose): 2.38 ± 0.44; rhinorrhea (runny nose): 2.41 ± 0.44; nasal itching (itchy nose): 2.07 ± 0.60; sneezing (sneezing); 1.97 ± 0.67; The data are presented as score, mean change from baseline (± SE). □, Placebo; ●, montelukast 10 mg; ♢, montelukast 20 mg; ▴, loratadine; ○, montelukast 10 mg with loratadine 10 mg. Montelukast with loratadine improved each individual nasal symptom compared with all other treatment groups (P < .05), except for nasal congestion score, which was not significantly different from that for montelukast 10 mg. Journal of Allergy and Clinical Immunology 2000 105, 917-922DOI: (10.1067/mai.2000.106040) Copyright © 2000 Mosby, Inc. Terms and Conditions

Fig. 2 Effect of treatment on the rhinoconjunctivitis quality of life on the pooled seven domains. A 7-point scale (0 = best; 6 = worst) was used. Upper limits of 95% CI are shown. Journal of Allergy and Clinical Immunology 2000 105, 917-922DOI: (10.1067/mai.2000.106040) Copyright © 2000 Mosby, Inc. Terms and Conditions

Fig. 3 Patients’ global evaluations of overall allergic rhinitis symptoms. A 0 (very much better) to 6 (very much worse) scale was used. Data are presented as percentage of patients rating themselves as better (scores = 0, 1, 2), no change (score = 3), or worse (scores = 4, 5, 6). Journal of Allergy and Clinical Immunology 2000 105, 917-922DOI: (10.1067/mai.2000.106040) Copyright © 2000 Mosby, Inc. Terms and Conditions

Fig. 4 Onset of action. Treatment effects on daytime nasal symptoms during the first 3 days of the treatment period. Data are presented as scores, mean change from baseline (± SE). □, Placebo ; ●, montelukast 10 mg; ♢, montelukast 20 mg; ▴, loratadine; ○, montelukast 10 mg with loratadine 10 mg. Montelukast with loratadine was significantly (P < .05) different from placebo, montelukast 20 mg, and loratadine 10 mg on the first day of treatment. Journal of Allergy and Clinical Immunology 2000 105, 917-922DOI: (10.1067/mai.2000.106040) Copyright © 2000 Mosby, Inc. Terms and Conditions